Introduction

Neuroscientific Approach to Emotions and Feelings: The Last Frontier of the New Millennium
By Donatella Marazziti, MD For centuries, emotions and feelings have been considered a domain of poets, writers, novelists, or psychologists who have tried to explore their secretive natures. They have been debating the crucial question of what they are, without providing any exhaustive answer except magnificent descriptions of them or sophisticated psychodynamic interpretations.
However, the explosion of neuroscience that has occurred in the last decades has provoked a real revolution and reshaping of previous knowledge. In addition, the increasing amount of data that are accumulating permits nowadays a detailed description, in molecular terms, of some brain processes in both physiological and pathological conditions. We do not know as yet how the brain produces the mind, but we cannot disregard anymore that the mind is a product of the brain.
Following this line of thought, emotions and feelings, such as attachment, pair and parental bonding, boredom, shyness and even love, typical of higher mammals and neglected for centuries by experimental sciences, have become the topic of extensive neuroscientific research in order to elucidate their biological mechanisms. This is in spite of the fact that there exist as yet concrete problems for research in this field. First, scientific methods often appear inappropriate to explore the personal characteristics of emotions that always show peculiarities linked to the particular individual, 1 and no standardized method is adequate to cover the range of the multiple expressions of them. Secondly, some feelings, such as love, seem to have no correpondent models in animals that are of valuable help in several cases. Because of these biases, perhaps, research in this area has been mainly neglected; however, we cannot disregard also the skepticism and the meager interest in investigating "feelings" rather than "real disorders." 2 For a long time, in fact, feelings have not been considered worthy enough as topics of experimental science and, therefore, their intimate nature has never been investigated rigorously. However, we are of the opinion that it is now time to move ahead. We can easily predict that in the future we shall be able to unravel how the brain functions and dysfunctions and how emotions and feelings emerge from its activity, without disregarding the role of cultural and enviromental factors that probably are more involved in shaping rather than in determining them.
This issue of CNS Spectnims aims to present an overview of the latest research on the psychobiological mechanisms regulating some emotions and feelings. Domenico Canele, MD, and Stephanie Pistoia, MD, write about the neuroendocrine control of libido, a drive which is essential for the species survival. Boredom is the topic of Carlo Maggini's, MD, paper, which presents the current hypotheses on the pathophysiology of this feeling, while Stefano Pallanti, MD, and Leonardo Quercioli, MD, present an extensive review on shame from physiology to pathology. The paper of Silvana Galderisi, MD, PhD, and Armida Mucci, MD, PhD, is focused on emotional reactivity and on how it can be linked to vulnerability towards psychopathology.
Obviously, the topics are limited due to the physical constraints of the journal, but we want to stress the need for further reflection and research in this area that, according to us, represents the real challenge for neuroscience in the third millennium. In addition, we strongly believe that the identification of the neural substrates of human feelings and emotions might represent the glue to reconcile psychology and psychiatry, both with the same basis in the human "*^B%
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Effective first-line SSRI therapy with a favorable side-effect profile Incidence of insomnia, anxiety, agitation, nervousness, and fatigue comparable to placebo Not associated with clinically significant long-term weight changes Efficacy proven in the treatment of depression Once-daily 20 mg starting dose for all patients
The most frequent adverse events reported with CELEXA vs placebo in clinical triais were nausea (21 % vs 14%), dry mouth (20% vs 14%), somnolence (18% vs 10%), insomnia (15% vs 14%), increased sweating (11% vs 9%), tremor (8% vs 6%), diarrhea (8% vs 5%), and ejaculation disorder (6% vs 1%). CELEXA is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or in patients with a hypersensitivity to citaiopram HBr or any of the ingredients in CELEXA. CELEXA therapy was associated with a mean weight increase of only 1.5 kg after 12 months. 20 mg/day is the recommended dose for most elderly patients and patients with hepatic impairment, with titration to 40 mg/day only for nonresponding patients. Brief Summary: For complete detate, please see tuH prescribing information for Cetexa. INDICATIONS AND USAGE Celexa (citalopram HBr) is indicated for the treatment of depre sion, The efficacy of Celexa in the treatment of depression was established in 4-to 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder. A major depressive episode (DSM-IV) implies a prominent and relatively persistent {nearly every day for at least 2 weeks) depressed or dysphonc mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, s g nificant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of Celexa in hospitalized depressed patients has not been adequately studied. The efficacy of Celexa in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controlled trials. Nevertheless, the physician who elects to use Celexa for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. CONTRAINDICATIONS Concomitant use in patients taking monoamine oxidase inhibitors (MAOI's) is contraindicated (see WARNINGS). Celexa is contraindicated in patients with a hypersensitivity to citalopram or any of the inactive ingredients in Celexa. WARNINGS Potential for Interaction with Monoamine Oxidase Inhibitors In patients receiving serotonin reuptake inhibitor drugs in combination with a monoamine oxidase inhibitor (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myodonus, autonotnic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma. These reactions have also been reported in patients who have recently discontinued SSRI treatment and have been started on an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Furthermore, limited animal data on the effects of combined use of SSRI's and MAOI's suggest that these drugs may act synergistically to elevate blood pressure and evoke behavioral excitation. Therefore, it is recommended that Celexa should not be used In combination with an MAOI, or within 14 days of discontinuing treatment wrth an MAOI. Similarly, at least 14 days should be allowed after stopping Celexa before starting an MAOI. PRECAUTIONS General Hvponatremia Several cases of hyponatremia and SIADH (syndrome of inappropriate antidiuretic hormone secretion) have been reported in association with Celexa treatment. All patients with these events have recovered with discontinuation of Celexa and/or medical intervention, Activation of Mania/Hvpomania In placebo-controlled trials of Celexa,some of which included patients with bipolar disorder, activation of mania/hypomania was reported in 0,2% of 1063 patients treated with Celexa and in none of the 446 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antidepressants. As with all antidepressants, Celexa should be used cautiously in patients with a history of mania. Seizures Although anticonvulsant effects of citalopram have been observed in animal studies, Celexa has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the product's premarketing testing, In clinical trials of Celexa, seizures occurred in 0.3% of patients treated with Celexa (a rate of one patient per 98 years of exposure) and 0.5% of patients treated with placebo (a rate of one patient per 50 years of exposure), Like other antidepressants, Celexa should be introduced with care in patients with a history of seizure disorder. Suicide The possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Close supervision of high-risk patients should accompany initial drug therapy. Prescriptions for Celexa should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Interference With Cognitive and Motor Performance In studies in normal volunteers, Celexa in doses of 40 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactive drug may impair judgement, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities. Use in Patients With Concomitant illness Clinical experience with Celexa in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Celexa in patients with diseases or conditions that produce altered metabolism or hemodynamic responses. Celexa has not been systematically evaluated in patients with a recent history of myocarolal infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's prerrarketing testing. However, the electrocardiograms of 1116 patients who received Celexa in clinical trials were evaluated, and the data indicate that Celexa is not associated with the development of clinically significant ECG abnormalities. In subjects with hepatic impairment, citalopram clearance was decreased and plasma concentrations were increased. The use of Celexa in hepatjcally impaired patients should be approached with caution and a lower maximum dosage is recommended. Because citalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment with Celexa, however, it should be used with caution in such patients. Drug Interactions CNS Drugs -Given the primary CNS effects of citalopram, caution should be used when it is taken in combination with other centrally acting drugs. Alcohol -Although citalopram did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by depressed patients taking Celexa is not recommended. Monoamine Qxidase Inhibitors (MAPI's) -See CONTRAINDICATIONS and WARNINGS. Cimetidine -In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmai of 43% and 39%, respectively. The clinical significance of these findings is unknown. Diaoxin -In subjects who had received 21 days of 40 mg/day Celexa,combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. Lithium -Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lith urn. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice, Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Ceiexa and lithium are coadministered. W a i M ! -Administration of 40 mg/day Celexa for 21 days did not affect trie pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine -Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/Oay for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate, Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered. CYP3A4 and CYP2C19 Inhibitors -In vitro studies indicated that CYP3A4 and CYP2C19 are the primary enzymes involved in the metabolism of citalopram. As data are not available from clinical pharmacokinetic studies, the possibility that the clearance of citalopram will be decreased when citalopram is administered with a potent inhibitor of CYP3A4 (eg, ketoconazoie, itraconazoie, fluconazole, or erythromycin] or a potent inhibitor of CYP2C19 (eg, omeprazole) should be considered. Metoprolol -Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate. Imipramine and Other Tricvclic Antidepressants (TCA's) -In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the tricyclic antidepressant imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCA's with Celexa. Electroconvulsive Therapy (ECTi -There are no clinical studies of the combined use of electroconvulsive therapy (ECT) and Celexa. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Of 4422 patients in clinical studies of Celexa, 1357 were 60 and over, 1034 were 65 and over, and 457 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Most elderly patients treated with Celexa in clinical trials received daily doses between 20 and 40 mg. In two pharmacokinetic studies, citalopram AUC was increased by 23% and 30%, respectively, in elderly subjects as compared to younger subjects, and its half-life was increased by 30% and 50%, respectively. 20 mg/day is the recommended dose for most elderly patients. ADVERSE REAC-TIONS The premarketing development program for Celexa included citalopram exposures in patients and/or normal subjects from 3 different groups of studies: 429 normal subjects in clin-CELEXA™ (citalopram HBr) ical pharmacology/pharmacokinetic studies; 4422 exposures from patients in controlled and lcontrolled clinical trials, corresponding to approximately 1370 patient exposure years. There were, in addition, over 19,000 exposures from mostly open-label, European postmarketing tu e yne conditions and duration of treatment with Celexa varied greatly and included (in overlapping categories) open-label and double-blind studies, inpatent and outpatient studies, fixed-dose and dose-titration studies, and short-term and long-term exposure. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, ECGs, and results of ophthalmology examinations. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events withou* t g ouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO] terminology has been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatmentemergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Adverse Findings Observed in Short-term, Placebo-Controlled Trials Adverse Events Associated With Discontinuation of Treatment Among 1063 depressed patients who received Celexa at doses ranging from 10 to 80 mg/day in placebo-controlled trials of up to 6 weeks in duration, 16% discontinued treatment due to an adverse event, as compared to 8% of 446 patients receiving placebo. The adverse events associated with discontinuation and considered drug-related (ie, associated with discontinuation in at least 1 % of Celexa-treated patients and at a rate at least twice that of placebo) are shown in TABLE 1. It should be noted that one patient can report more than one reason for discontinuation and be counted more than once in this table. TABLE 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse events that occurred among 1063 depressed patients who received Celexa at doses ranging from 10 to 80 mg/day in placebo-controlled trials of up to 6 weeks in duration. Events included are those xcurring in 2% or more of patients treated with Celexa and for which the incidence in patients treated with Celexa was greater than the incidence in citalopram HBr
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placebo-treated patients. The prescriber should be aware that these figures cannot be used predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figjres, however, do provide the prescribing physician with some basis for estimating the relat je contribution of drug and nondrug factors to the adverse event incidence rate in the population studied. The only commonly observed adverse event that occurred in Celexa patients with an incidence of 5% or greater and at least twice the incidence in placebo a' : ert" 'v^s ejaculation disorder (primarily ejaculatory delay) in male patients (see TABLE 2 ). 'Events reported by at least 2% of patients treated with Celexa are reported, except for the following events which had an incidence in placebo > Celexa: headache, asthenia, dizziness, constipation, palpitation, vision abnormal, sleep disorder, nervousness, pharyngitis, micturition disorder, back pain. 'Denominator used was for females only (N=638 Celexa; N=252 placebo). 'Primarily ejaculatory delay. 'Denominator used was for males only (N=425 Celexa; N=194 placebo). Dose Dependency of Adverse Events The potential relationship between the dose of Celexa administered and the incidence of adverse events was examined in a fixed-dose study in depressed patients receiving placebo or Celexa 10,20,40, and 60 mg. Jonckheere's trend test revealed a positive dose response (JX.05) for the following adverse events; fatigue, impotence, insomnia, sweating increased, somnolence, and yawning, Male and Female Sexual Dysfunction With SSRI's Although changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling, are likely to underestimate their actual incidence. In placebo-controlled clinical trials (TABLE 2), the reported incidence of decreased libido, ejaculation disorder (primarily ejaculatory delay), and impotence in male depressed patients receiving Celexa {N=425) was 3.8%, 6.1%, and 2.8%, respectively. In female depressed patients receiving Celexa (N=638), the reported incidence of decreased libido and anorgasmia was 1.3% and 1.1 %, respectively. The reported incidence of each of these adverse events was <1.0% among male and female depressed patients receiving placebo. While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRI's, physicians should routinely inquire about such possible side effects. Vital Sign Changes Ceiexa and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with Celexa treatment. In addition, a comparison of supine and standing vital sign measures for Celexa and placebo treatments indicated that Celexa treatment is not associated with orthostatic changes. Weight Changes Patients treated with Celexa in controlled trials experienced a weight loss of about 0,5 kg compared to no change for placebo patients. Laboratory Changes Celexa and placebo groups were compared with respect to (1) mean change from baseline in various serum chemistry, hematology, and urinalysis variables and (2) the incidence of patents meeting criteria for potentially clinically significant changes from baseline in these variables, These anaiyses revealed no clinically important changes in laboratory test parameters associated with Celexa treatment. ECG Changes Electrocardiograms from Celexa (N=802) and placebo (N=241) groups were compared with respect to (1) mean change from baseline in various ECG parameters and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. The only statistically significant drugplacebo difference observed was a decrease in heart rate for Celexa of 1.7 bpm compared to no change in heart rate for placebo. There were no observed differences in QT or other ECG intervals. Other Events Observed During the Premarketing Evaluation of Celexa Following is a list of WHO terms that reflect treatment-emergent adverse events, as defined in the introduction to the ADVERSE REACTIONS section, reported by patients treated wrth Celexa at multiple doses in a range of 10 to 80 mg/day during any phase of a trial within the premarketing database of 4422 patients. Ail reported events are included except those already listed in TABLE 2 or elsewhere in labeling, those events for which a drug cause was remote, those event terms which were so general as to be uninformative, and those occurring in only one patient. It is important to emphasize that although the events reported occurred during treatment with Celexa.they were not necessarily caused by it, Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events r are those occurring in less than 1/100 patients but at least 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients, 
